Invivyd Revenue Jumps 413 Percent in Q2
Invivyd (NASDAQ:IVVD), a biotech firm focused on antibodies for infectious diseases, reported earnings for Q2 2025 on August 14, 2025. The company reported a sharp increase in GAAP revenue year over year, with net product revenue of $11.8 million compared to $2.3 million in Q2 2024, mainly from its COVID-19 monoclonal antibody PEMGARDA. However, GAAP revenue of $11.8 million undershot analyst expectations of $23.16 million by nearly half. The reported net loss per share was $(0.12) (GAAP). Despite substantial drops in research and development (R&D) and selling, general and administrative (SG&A) costs (GAAP), continued net losses and a shrinking cash position reflect the firm remains in investment mode. The quarter marked significant pipeline and regulatory advances.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Invivyd develops monoclonal antibody (mAb) medicines to prevent and treat infectious diseases, with a primary focus on COVID-19 and related viral threats. Its lead product, PEMGARDA, is an antibody authorized as a preventive therapy for COVID-19 in immunocompromised individuals under the U.S. Food and Drug Administration's Emergency Use Authorization (EUA) pathway. This population includes those who do not mount a strong response to vaccination, representing millions of at-risk patients in the U.S.
Source Fool.com
